Zhu, Jay-Jiguang
Goldlust, Samuel A.
Kleinberg, Lawrence R.
Honnorat, Jérôme
Oberheim Bush, Nancy Ann
Ram, Zvi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)
https://doi.org/10.1007/s12672-022-00555-5
Funding for this research was provided by:
Novocure® GmbH
Article History
Received: 29 June 2022
Accepted: 8 September 2022
First Online: 14 October 2022
Declarations
:
: As this was a post-marketing registry study, no ethical approval was required. All patients enrolled in the TTFields therapy registry and who met eligibility criteria had previously provided written informed consent prior to study enrollment, inclusive of use of protected health information.
: Not applicable.
: Jay-Jiguang Zhu has been supported by the following for-profit companies for clinical trials and contracted research with payments made to his institution: Denovo Biopharma, Novocure, Inc., Five Prime Therapeutics, Inc., Boston Biomedical of Sumitomo Dainippon Pharma Co., Ltd.Samuel A Goldlust has received honoraria for lectures, consultation or advisory board participation from the following: Daiichi Sankyo, Cellevolve, Sumitomo Dainippon Pharma Oncology, Physicians' Education Resource, Cornerstone Specialty Network, Novocure, Inc., Wex Pharmaceuticals, Bristol-Myers Squibb, Tocagen, Cortice Biosciences, and Boston Biomedical. SAG owns stock in COTA and received support for travel, accommodations, and expenses from the following: Wex Pharmaceuticals, Tocagen, Novocure, Inc., Boston Biomedical, Bristol-Myers Squibb, Cortice Biosciences, Caris Life Sciences, Kyowa Kirin International. The following have supported clinical trials and contracted research conducted by SAG with payments made to his institution: AbbVie, Acerta Pharma, Amgen, Boston Biomedical, Bristol-Myers Squibb, Cantex Pharmaceuticals, Celgene, Celldex, Cellularity, CNS Healthcare, Cortice Biosciences, Diffusion Pharmaceuticals, Immunocellular Therapeutics, Imvax, Karyopharm, Kazia, Merck, Northwest Biotherapeutics, Novocure, Novogen, Pfizer, Sanofi, Sumitomo Dainippon Pharma Oncology, Tocagen, Regeneron and Wex Pharmaceuticals.Lawrence Kleinberg has received honoraria for lectures, consultation, or advisory board from the following for-profit companies; Accuray and Novocure, Inc. The following for-profit companies have supported clinical trials and contracted research conducted by Lawrence Kleinberg with payments made to his institution: Arbor Pharmaceuticals, Accuray, Novartis, and Novocure, Inc.Jérôme Honnorat has received honoraria for lectures and advisory board participation from the following for-profit companies: Bristol-Myers Squibb, AbbVie, and Novocure, Inc.Nancy Ann Oberheim Bush has received honoraria for lectures, consultation or advisory board participation from the following for-profit company: GLC. The following for-profit companies have supported clinical trials and contracted research conducted by NAOB with payments made to her institution: Merck and Ziopharm.Zvi Ram serves as a consultant to Novocure, Inc.